Literature DB >> 19396009

Postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma.

Nobuhiro Takeshima1, Kuniko Utsugi, Katsuhiko Hasumi, Ken Takizawa.   

Abstract

We examined the effectiveness of postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma. During the period from 1994 to 2002, 98 consecutive patients with clinical stage I and II cervical adenocarcinoma were treated surgically without having undergone any prior treatment. Surgical procedures included radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy. Postoperatively, 21 patients were found to have lymph node metastasis, and all were treated with chemotherapy in the absence of radiotherapy. All patients were followed up for at least 5 years. Recurrence developed in 9 of the 21 patients, all 9 died of the disease. Six of the 9 recurrences were extrapelvic lesions. Five-year disease-free survival and overall survival were 57% and 67%, respectively. Recurrence was more common in patients with 6 or more positive nodes than in those with fewer than 3 positive nodes. These data suggest the potential role of postoperative chemotherapy for treatments of cervical adenocarcinoma. However, the effectiveness of chemotherapy alone in node-positive cervical adenocarcinoma was likely not as high as that in squamous cell carcinoma. Despite our use of postoperative chemotherapy in the absence of pelvic radiation, the disease recurred predominantly at distant sites.

Entities:  

Mesh:

Year:  2009        PMID: 19396009     DOI: 10.1111/IGC.0b013e31819c9fa0

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.

Authors:  Munetaka Takekuma; Yuka Kasamatsu; Nobuhiro Kado; Shiho Kuji; Aki Tanaka; Nobutaka Takahashi; Masakazu Abe; Yasuyuki Hirashima
Journal:  Int J Clin Oncol       Date:  2016-02-08       Impact factor: 3.402

2.  Adjuvant chemotherapy for early-stage cervical cancer.

Authors:  Hiroshi Asano; Yukiharu Todo; Hidemichi Watari
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.